Authors: J. Válková; J. Staňková; P. Kavan; E. Kabíčková; P. Gajdoš; J. Koutecký Authors‘ workplace: Klinika dětské onkologie 2. LF UK a FNM, Praha Published in: Čas. Lék. čes. 2002; : 316-319 Category:
Background.Amifostine (WR-2721,Ethyol)is a chemoprotective agent.There is little experiences with amifos-tine application in megachemotherapy in children.We evaluated amifostine effect on the reduction of the acutetoxicity.Methods and Results.Retrospective comparison of patients who received amifostine with the control group (72vs.72).Amifostine 750 mg/m2was given 15 minute before cytostatic dose and regularly each eight hours if weadministered cytostatics continuously.Megachemotherapy schedule included melfalan,carboplatin,cyklophospha-mid,vepesid,busulfan,thiotepa and karmustin.Type of graft:peripheral stem cells 56 vs.29,bone marrow 8 vs.30,combination 8 vs.13.Nonhematological toxicity:mucositis p=0.047,hepatotoxicity p
Key words: amifostine,megachemotherapy,acute toxicity reduction.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
